MRI-guided risk stratification for neoadjuvant immunotherapy in rectal cancer - Takeaways - MDSpire

MRI-guided risk stratification for neoadjuvant immunotherapy in rectal cancer

  • By

  • Jiali Zhang

  • Feng Tian

  • Yue Shang

  • Honghai Dai

  • Shuo Zhang

  • Bing Kang

  • Jiaxiang Xin

  • Ximing Wang

  • Changqing Jing

  • Cong Sun

  • May 29, 2026

  • 0 min

Share

  • 1

    This study evaluated MRI-based risk assessment for predicting pathological complete response in locally advanced rectal cancer patients.

  • 2

    A three-factor MRI risk score was developed, predicting pCR with an AUC of 0.835 based on mrEMVI, mrMRF, and tumor length.

  • 3

    In MRI-defined high-risk patients, the nICRT group showed a significantly higher pCR rate compared to the nCRT group.

  • 4

    The study included 135 patients, with 43 in the nICRT group and 92 in the nCRT group, utilizing various neoadjuvant treatment regimens.

  • 5

    Findings suggest that MRI-based stratification may help identify subgroups with different responses to neoadjuvant treatments, warranting further validation.

Original Source(s)

MRI-guided risk stratification for neoadjuvant immunotherapy in rectal cancer

  • by Jiali Zhang, Feng Tian, Yue Shang, Honghai Dai, Shuo Zhang, Bing Kang, Jiaxiang Xin, Ximing Wang, Changqing Jing, Cong Sun

  • May 29, 2026

Related Content

Real-world healthcare resource use and costs associated with the management of locally advanced head and neck cancer in Portugal – TRACE2 study

Financial Hardship and Nonadherence to Lifestyle and Surveillance in Childhood Cancer Survivors

Lenvatinib induces ferroptosis-related changes in osteosarcoma cells involving the p-STAT3/p53/xCT axis